Transcript
At ASH 2024, this year there were so many exciting abstracts and multiple myeloma, but I would like to highlight one particular abstract. Abstract 361 was a study that was presented looking at the role and duration of lenalidomide maintenance. The standard of care for patients who are transplant-eligible and have multiple myeloma is induction therapy followed by autologous transplant and lenalidomide maintenance. The duration of lenalidomide maintenance is unclear and often patients continue it until progression of disease. In this study, the researchers tested for MRD measurable residual disease following autologous transplant, and when patients had MRD-negative disease for three years, they stopped lenalidomide maintenance. This study was really practice-changing because they found that thirty months after stopping lenalidomide, about 90% of patients remained MRD negative. And so this suggests that it is safe to stop lenalidomide maintenance after three years of MRD negativity following autologous transplant.
